

## **Provisional 2026 EPHMRA ATC Developments**

The following new class structures were voted on by EPHMRA/Intellus in May/June 2025 and agreed in principle. These structures will now be used in the next part of the development process which is the detailed refinement of the rules.

Please note that these new class structures are provisional at this time. The 2026 codes, descriptions and Guideline text will be finalised and published by the Committee at the end of 2025. The new structures then come into effect from the beginning of 2026.

### **Immunosuppressants - Complement Inhibitors**

New third level class within L4 (Immunosuppressants) for products containing complement inhibitors indicated for multiple conditions. Currently, these products are classified in L4X (Other immunosuppressants).

<b>L4E</b>	<b>COMPLEMENT INHIBITORS</b>
	<p>Includes products containing complement inhibitors, eg eculizumab, iptacopan, pozelimab, ravulizumab, etc. These products are indicated for multiple conditions, eg atypical haemolytic uraemic syndrome (aHUS), CHAPLE disease, generalised myasthenia gravis (gMG), neuromyelitis optica spectrum disorder (NMOSD), paroxysmal nocturnal haemoglobinuria (PNH), etc.</p> <p>Products containing complement inhibitors: for haemolysis in cold agglutinin disease only are classified in B3X; for hereditary angioedema only are classified in B6D; for atypical haemolytic uraemic syndrome (aHUS) and/or paroxysmal nocturnal haemoglobinuria (PNH) only are classified in B6X; for vasculitic conditions only, eg granulomatosis with polyangiitis, are classified in C6X; for kidney conditions only, eg IgA nephropathy, are classified in G4X; for generalised myasthenia gravis (gMG) only are classified in M5X; for geographic atrophy only are classified in S1X.</p>

### **Immunosuppressants - Calcineurin Inhibitors**

New third level class within L4 (Immunosuppressants) for products containing calcineurin inhibitors. Currently, these products are classified in L4X (Other immunosuppressants).

<b>L4F</b>	<b>CALCINEURIN INHIBITORS</b>
	<p>Includes products containing calcineurin inhibitors, eg ciclosporin, tacrolimus, etc. for the prevention and treatment of organ transplant rejection, graft versus host disease etc.</p> <p>Products containing calcineurin inhibitors are classified in D5 if only for skin conditions (eg topical forms of tacrolimus for atopic dermatitis) and in S1 if only for ophthalmological conditions. Products containing voclosporin are classified in G4X.</p>

## Orexin Antagonists

New fourth level class within N5B (Hypnotics/Sedatives) for products containing orexin receptor antagonists. Currently, these products are classified in N5B1 (Non-barbiturates, plain).

<b>N5B6</b>	<b>Orexin Antagonists</b>
	Includes products containing orexin receptor antagonists, eg daridorexant, lemborexant, suvorexant etc. for insomnia.